Save Product
Product Details
Source
Anti-SARS-CoV-2 Spike RBD Antibody, Chimeric mAb, Human IgG1 (AM130) (S1N-M130) is a chimeric monoclonal antibody recombinantly expressed in HEK293 cells, which combines the variable regions of a mouse monoclonal antibody with human IgG1 constant domains. The variable regions was obtained from a mouse immunized with purified recombinant SARS-CoV-2 Spike S1 Protein. This antibody can broadly recognize all Variants of Concerns (VOCs), including Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), Delta (B.1.617.2) and Omicron (B.1.1.529).
Antibody Type
Recombinant Monoclonal
Clone
AM130
Isotype
Human IgG1, Kappa
Host Species
Mouse
Reactivity
Virus
Specificity
This product is a specific antibody against SARS-CoV-2 Spike protein RBD domain. No cross-reactivity is detected with Spike protein RBD domain of other coronaviruses, including SARS-CoV, MERS-CoV, HCoV-229E, HCoV-NL63, HCoV-OC43 and HCoV-HKU1.
Application
ApplicationRecommended UsageELISA0.2-2 μg/mLPurification
Protein A purified.
Concentration
Please refer to the Certificate of Analysis (CoA).
Form
Lyophilized
Formulation
Lyophilized from a 0.22 μm-filtered solution in PBS (pH 7.4), with trehalose as protectant.
Please contact us for customized product forms or formulations.
Reconstitution
Please refer to the Certificate of Analysis (CoA) for specific instructions.
Shipping
Lyophilized product is shipped at ambient temperature.
Storage
For long term storage, the product should be stored in a lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
- -20°C to -70°C for 12 months in lyophilized state;
- -70°C for 3 months under sterile conditions after reconstitution.
Notices
Product Specific Notices: For research use only.
ACRO Quality Management System
Customers Also Viewed
Performance Data
Bioactivity-ELISA
Immobilized SARS-CoV-2 S1 protein, His Tag (Cat. No. S1N-C52H2) at 2 μg/mL (100 μL/well) can bind Anti-SARS-CoV-2 Spike RBD Antibody, Chimeric mAb, Human IgG1 (Cat. No. S1N-M130) with a linear range of 0.2-3 ng/mL (QC tested).
Protocol
Immobilized Anti-SARS-CoV-2 Spike RBD Antibody, Chimeric mAb, Human IgG1 (S1N-M130) at 1 μg/mL (100 μL/well) can bind SARS-CoV-2 Spike Trimer, His Tag (B.1.1.529/Omicron) (Cat.No. SPN-C52Hz) with a linear range of 0.04-0.125 μg/mL (Routinely tested).
Protocol
Immobilized Anti-SARS-CoV-2 Spike RBD Antibody, Chimeric mAb, Human IgG1 (S1N-M130) at 1μg/mL (100 μL/well) can bind SARS-CoV-2 Spike RBD, His Tag (B.1.1.529/Omicron) (Cat.No. SPD-C522e) with a linear range of 0.0005-0.004 μg/mL (Routinely tested).
Protocol
Bioactivity-BLI
Loaded Anti-SARS-CoV-2 Spike RBD Antibody, Chimeric mAb, Human IgG1 (Cat. No. S1N-M130) on AHC Biosensor, can bind SARS-CoV-2 S protein RBD, His Tag (Cat. No. SPD-C52H3) with an affinity constant of 0.603 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).
Protocol
Loaded Anti-SARS-CoV-2 Spike RBD Antibody, Chimeric mAb, Human IgG1 (Cat. No. S1N-M130) on AHC Biosensor, can bind SARS-CoV-2 S protein RBD (N501Y), His Tag (Cat. No. SPD-C52Hn) with an affinity constant of 1.38 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).
Protocol
Loaded Anti-SARS-CoV-2 Spike RBD Antibody, Chimeric mAb, Human IgG1 (Cat. No. S1N-M130) on AHC Biosensor, can bind SARS-CoV-2 S protein RBD (K417N, E484K, N501Y), His Tag (Cat. No. SPD-C52Hp) with an affinity constant of 1.10 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).
Protocol
Loaded Anti-SARS-CoV-2 Spike RBD Antibody, Chimeric mAb, Human IgG1 (Cat. No. S1N-M130) on AHC Biosensor, can bind SARS-CoV-2 S protein RBD (K417T, E484K, N501Y), His Tag (Cat. No. SPD-C52Hr) with an affinity constant of 1.07 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).
Protocol
Loaded Anti-SARS-CoV-2 Spike RBD Antibody, Chimeric mAb, Human IgG1 (Cat. No. S1N-M130) on AHC Biosensor, can bind SARS-CoV-2 Spike RBD (L452R, T478K), His Tag (Cat. No. SPD-C52Hh) with an affinity constant of 1.03 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).
Protocol
Loaded Anti-SARS-CoV-2 Spike RBD Antibody, Chimeric mAb, Human IgG1 (Cat. No. S1N-M130) on AHC Biosensor, can bind SARS-CoV-2 Spike RBD, His Tag (BA.2/Omicron) (Cat. No. SPD-C522g) with an affinity constant of 1.04 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).
Protocol
Customer Reviews Writing Reviews
M***g2022-04-16
LikesOrdered AM130 as a binding control for ACE2 competition experiments with a panel of SARS-CoV-2 variant RBDs. This antibody worked incredibly well, showing strong binding (BLI) against all variants tested. As mentioned in the description, this is not a neutralizing antibody and it does not block ACE2, which made it a perfect binding control to ensure that the RBDs were in good shape and functional. Overall would highly recommend this product.
FAQ
- product
Can lyophilized proteins remain stable during room-temperature shipping or temporary room-temperature exposure?
In general, lyophilized proteins remain stable during room-temperature shipping or temporary exposure to room-temperature conditions.
Many ACROBiosystems recombinant proteins are supplied in lyophilized (freeze-dried) form. The lyophilization process effectively removes moisture from the product, helping reduce degradation-related reactions and improve protein stability during transportation and storage.
To evaluate the stability of lyophilized proteins under normal temperature conditions, ACROBiosystems conducted a stability study on 11 representative lyophilized protein products at 37°C. The study demonstrated that these proteins maintained good quality stability after storage at 37°C for approximately 20 days. Based on these validation results, temporary room-temperature exposure during shipping or handling is generally not expected to have a significant impact on product quality or downstream application performance.
To ensure optimal long-term stability, products should be stored according to the storage conditions specified in the product Certificate of Analysis (COA) upon receipt.
Supporting Document
Background
Recent Advances
Contact Us
[North America]: +1 800-810-0816
[Switzerland]: +41 800 040 012
[Asia & Pacific]: +86 400-682-2521
Drug Candidate Licensing
